Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

The Intra-arterial Vasospasm Trial

ClinicalTrials.gov ID: NCT01996436

Public ClinicalTrials.gov record NCT01996436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The Intra-arterial Vasospasm Trial - A Multi-center Randomized Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to determine the optimal intra-arterial drug treatment regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome at 90 days post discharge following optimal intra-arterial drug treatment for cerebral vasospasm. We hypothesize that Intra-arterial (IA) infusion of a combination of multiple vasodilators is more efficacious than single agent treatment cerebral vasospasm therapy. All procedures done as a part of this study are standard hospital care procedures done to treat cerebral vasospasm and all drugs to be used are FDA approved.

Study identification

NCT ID
NCT01996436
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Peng Roc Chen, MD
Other
Enrollment
92 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2016 (Actual)
Primary completion
Apr 29, 2024 (Actual)
Completion
Aug 12, 2024 (Actual)
Last update posted
May 11, 2025

2016 – 2024

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Yale School of Medicine New Haven Connecticut 06520 —
Northwell Health Manhasset New York 11030 —
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 —
Geisinger Clinic Danville Pennsylvania 17822 —
University of Texas Medical School at Houston Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01996436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 11, 2025 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01996436 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →